Ursodeoxycholic Acid JG

Quick links

Choose a section

Quick links to important sections

Advertisements

Ursodeoxycholic Acid JG

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Ursodeoxycholic Acid JG

Quick Facts About Ursodeoxycholic Acid

Property Description
Active ingredient Ursodeoxycholic acid (UDCA), also known as Ursodiol
Form Oral solid dosage (Capsules or tablets)
Pharmacological class Hepatoprotective agent, Cholelitholytic agent
Common use Modulating bile composition and promoting bile flow
Origin Derived secondary bile acid, manufactured for pharmaceutical use

What is Ursodeoxycholic Acid (Ursodiol)?

Ursodeoxycholic Acid (UDCA), the active ingredient known as Ursodiol, is a specialized secondary bile acid derivative manufactured as an oral solid dosage form for oral administration. This medication is classified as a prescription drug due to its specific mechanisms of action and required monitoring. This substance is highly hydrophilic (water-soluble) and is used therapeutically because its chemical structure is significantly less toxic than most natural bile acids present in the body.

The product designation, such as Ursodeoxycholic Acid JG, ensures a single-ingredient formulation standardized for consistent delivery. UDCA is clinically recognized for its ability to alter the balance of cholesterol saturation in bile. This confirms the medication's primary role is to protect the health of the liver and regulate the flow of bile.


What Type of Medicine is UDCA? (Pharmacological Class and Purpose)

UDCA is classified primarily as a Hepatoprotective agent and a Cholelitholytic agent. The hepatoprotective function means the medicine actively helps to stabilize and shield the cell membranes of the liver (hepatocytes) from potential damage, a key attribute in managing chronic hepato-biliary issues. The cholelitholytic action indicates its ability to influence the composition of bile itself.

Ursodeoxycholic Acid is used for conditions where its ability to change bile composition and flow is beneficial, confirming its pharmacological role. This shows the drug’s general purpose is to support the body's natural processes by improving bile quality and flow. By competing with more hydrophobic bile acids, UDCA effectively creates a safer fluid environment within the biliary tract, supporting overall liver function.

Regulatory References

  1. LiverTox: Ursodiol (Ursodeoxycholic Acid)
Advertisements

What side effects are possible with Ursodeoxycholic Acid JG?

Possible Side Effects and Safety Information

Adverse reactions associated with Ursodeoxycholic Acid are classified in official regulatory documents based on frequency and affected body system. The most commonly reported effects typically involve the Gastrointestinal system, while more serious reactions are classified as very rare.

Frequency-Classified Adverse Reactions

Frequency Classification Documented Adverse Reactions System-Organ Class
Very Common (ge 1/10) Diarrhea, Pasty stools Gastrointestinal
Common (ge 1/100 to < 1/10) Abdominal pain, Nausea, Vomiting, Headache, Alopecia Gastrointestinal, Nervous System, Skin
Very Rare (< 1/10,000) Hepatic cirrhosis decompensation, Gallstone calcification, Urticaria Hepatobiliary, Skin

Serious Adverse Reactions and Safety Constraints

Very Rare Serious Events include the decompensation of hepatic cirrhosis, which has been observed in patients with advanced Primary Biliary Cholangitis (PBC). Additionally, the calcification of gallstones is a very rare event noted during gallstone dissolution therapy.

The official labeling documents several safety-related restrictions and situations where the medicine is contraindicated. These include pre-existing conditions such as acute inflammation of the gallbladder or biliary tract, occlusion of the biliary tract, the presence of radio-opaque calcified gallstones, and hypersensitivity to bile acids.

Population-Specific Safety Notes specify that women of child-bearing potential must use effective non-hormonal contraception, reflecting regulatory concerns from non-human studies.

The occurrence of diarrhea and loose stools is documented as potentially dose-dependent, a pattern where the effect may resolve upon dose reduction.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is derived from official government regulatory documents detailing the documented manifestations of overdose with Ursodeoxycholic Acid (Ursodiol) and the required emergency actions.


Documented Overdose Profile

The most likely clinical manifestation of a severe overdose with ursodeoxycholic acid is diarrhea (loose, watery stools), as noted in regulatory prescribing information. The official documents state that the occurrence of other severe symptoms is generally considered unlikely. This is due to the pharmaceutical characteristic that the substance’s absorption decreases as the administered dose increases, leading to excretion of the excess substance.

Furthermore, official regulatory documents, such as the FDA prescribing information, report no known cases of accidental or intentional human overdosage with ursodiol.

Overdose Component Regulatory Statement
Primary Manifestation Diarrhea
Severe Outcomes Other severe systemic symptoms are unlikely
Antidote No specific counter-measures or antidote are described

Required Emergency Actions

If an overdose is suspected, regulatory guidance mandates that an individual seek immediate medical attention by calling a Poison Control center or emergency services.

Treatment for the consequences of overdose, primarily severe diarrhea, must be managed through symptomatic treatment. This officially described supportive measure involves the restoration of fluid and electrolyte balance to address the effects of persistent loose stools, as directed by regulatory authorities.

Advertisements

Therapeutic Uses of Ursodeoxycholic Acid JG

What Ursodeoxycholic Acid JG Treats: Main Uses and Benefits

Ursodeoxycholic Acid is used in clinical settings that involve systemic stress related to chronic liver and biliary conditions. This medication is centrally applied in the management of Primary Biliary Cholangitis (PBC), a chronic condition where functional stability may be affected.

The primary therapeutic applications include its role in the long-term management of PBC, supportive use in addressing specific small, non-calcified cholesterol gallstones, and the provision of symptomatic relief for cholestasis-related pruritus (itching), including its use in Intrahepatic Cholestasis of Pregnancy. This medication provides support that contributes to easing the overall symptom load and is used for managing symptom clusters that may become disruptive. It is often used when symptoms intensify and supportive relief is needed, assisting with maintaining functional stability in the biliary system, and is relevant for use in settings where non-surgical management is appropriate for specific gallstone concerns.

Quick Fact: Relief for Biliary Discomfort
UDCA is relevant for easing symptoms related to physical discomfort, specifically pruritus, thereby supporting general well-being during symptomatic phases.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Ursodeoxycholic Acid

Regulatory documents strictly define the patient populations eligible for treatment with Ursodeoxycholic Acid (UDCA), based on specific health status and demographics. This information is derived from official regulatory labeling.

Contraindicated Populations

UDCA is contraindicated (must not be used) in patients with several conditions, including:

  • Known hypersensitivity to bile acids or any component of the formulation.
  • Complete biliary obstruction or acute inflammation of the gallbladder or bile ducts.
  • Impaired gallbladder contractility (non-functioning gallbladder).
  • Radio-opaque calcified gallstones (UDCA is only indicated for radiolucent, cholesterol stones).
  • Patients with frequent episodes of biliary colic.

Eligibility and Restriction Status

Population Group Regulatory Status
Adults (PBC/Gallstones) Established use for approved indications.
Pediatric Patients Use is limited to hepatobiliary disorders associated with cystic fibrosis (ages 6-18); general use is not established.
Pregnancy Not recommended; must not be used unless clearly necessary. Reliable contraception is required for women of childbearing potential.
Decompensated Cirrhosis Restricted; treatment may require discontinuation if liver function worsens.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ursodeoxycholic Acid's (UDCA) interaction profile focuses on agents that either interfere with its efficacy or alter the systemic exposure of co-administered drugs, based strictly on government regulatory labeling.


Interactions Affecting UDCA Absorption

Certain substances reduce the systemic absorption of Ursodeoxycholic Acid by binding to it in the intestine. These agents include Bile Acid Sequestering Agents (e.g., cholestyramine) and Aluminum-based Antacids. If the use of these binding agents is necessary, a timing separation rule must be applied: they are to be taken at least 2 hours before or 2 hours after the dose of UDCA, as stated in regulatory documents.


Therapeutic Antagonism and Restriction

Medicines that increase cholesterol secretion into the bile, such as Estrogens, Oral Contraceptives, and Fibrates (e.g., clofibrate), directly counteract the therapeutic action of UDCA. For this reason, regulatory restrictions state that co-administration with these agents must be avoided.


Altered Exposure of Co-administered Drugs

UDCA can alter the pharmacokinetics of other drugs. Its co-administration can significantly increase the intestinal absorption and exposure of Cyclosporine. When these are co-administered, regulatory guidance requires mandatory blood concentration monitoring of Cyclosporine and subsequent dose adjustment. Furthermore, UDCA has been documented to reduce the plasma concentrations of certain drugs, including the calcium antagonist Nitrendipine, and may reduce the therapeutic effect of Dapsone.

Advertisements

Mechanism of Action

How Ursodeoxycholic Acid JG Works

Ursodeoxycholic Acid (UDCA) operates through three primary and distinct mechanistic domains that modulate the bile and cellular function. The overall action is centered on altering the physiochemical properties of bile and modulating plasma membrane stability.

️ Cytoprotection and Competitive Bile Acid Displacement

This mechanism involves UDCA, a hydrophilic bile acid, substituting itself for the more chemically damaging hydrophobic bile acids within the enterohepatic circulation. It incorporates directly into the cell membranes of liver and bile duct cells, influencing their structure and modulating their susceptibility to toxicity. This competitive displacement reduces the concentration of toxic substances and modulates the molecular signaling that triggers apoptosis (cell death).

Modulation of Bile Cholesterol Saturation

UDCA lowers the cholesterol saturation index of bile by reducing the secretion of cholesterol from the liver and hindering its intestinal reabsorption. This facilitates the formation of highly stable mixed micelles with cholesterol. This action reduces the potential for cholesterol to precipitate and contributes to the physical dissolution of existing cholesterol-rich solid material in the biliary system.

Choleretic Action and Biliary Flow Enhancement

UDCA acts as a choleretic agent by promoting the secretion of bile. It achieves this by modulating the activity of key membrane transporters, such as the Chloride-Bicarbonate Anion Exchanger (AE2), in the bile duct cells. This mechanism increases the flow of bicarbonate and water into the bile ducts, increasing the volume of bile and supporting a generalized increase in the flow of the biliary system.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Ursodeoxycholic Acid JG

Ursodeoxycholic Acid (UDCA) is an orally administered medication available as capsules and tablets in various strengths (e.g., 250 mg, 300 mg, 500 mg), with dosing highly dependent on body weight and the specific condition being addressed.

Dosing and Administration Rules:

  • Route: The approved route is oral administration (by mouth).
  • Dosage: The adult dosage is generally determined based on body weight, typically ranging from 8-15 mg per kg of body weight per day. Pediatric dosing for conditions like cystic fibrosis-associated hepatobiliary disorders is also weight-based.
  • Frequency: The total daily dose is usually administered in two to four divided doses. Some regimens, such as for gallstone dissolution, may permit a larger portion or the entire dose to be taken once daily at night.
  • Timing: UDCA must be taken with food (after meals) to maximize absorption and efficacy.
  • Preparation and Handling: Capsules should be swallowed whole. Scored tablets may be broken in half along the score line to achieve the correct dose but must be swallowed unchewed with water. Do not take broken segments that have sat in the mouth.
  • Drug Separation: Medications like antacids containing aluminum hydroxide and bile acid sequestering agents (e.g., cholestyramine) must be administered at least 2 hours before or after Ursodeoxycholic Acid JG, as they can significantly inhibit its absorption.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ursodeoxycholic Acid JG


Evidence for Key Clinical Areas

The research supporting Ursodeoxycholic Acid (UDCA) for the long-term management of Primary Biliary Cholangitis (PBC) includes Randomized Controlled Trials (RCTs) and extensive long-term observational studies. Researchers primarily examined outcomes related to survival free of the need for liver transplantation and changes in key liver biochemical markers. Studies tracked outcomes and observed patterns where patients with improved liver markers were associated with better long-term outcomes. However, early RCTs provided limited insight into the definitive impact on overall survival alone, and the approach for managing the subgroup of patients whose markers show an inadequate change during the study period remains an area of uncertainty.

For Gallstone Dissolution, research explored UDCA's application in adults with small, non-calcified cholesterol gallstones. The studies' primary measure was the rate of complete dissolution, and findings indicate that reports of dissolution were consistently linked only to the cholesterol-type gallstones. A key limitation noted is that follow-up research examined the risk of stone recurrence after study medication stopped, meaning the durability of the initial observation is not fully established.

Research on Intrahepatic Cholestasis of Pregnancy (ICP) monitored changes in maternal pruritus severity and composite perinatal outcomes. Studies described patterns related to changes in maternal itching severity and in bile acid markers. Research findings regarding the single, rare outcome of stillbirth remain inconclusive, mainly because this specific event occurs rarely, limiting the ability of studies to draw definitive conclusions.


Evidence in Special Populations and Research Gaps

Research has explored the use of UDCA in certain specialized patient groups, including studies conducted in the pediatric population (children and adolescents) with Cystic Fibrosis-Associated Liver Disease (CFAHD). These trials monitored physiological strain using hepatic biochemical markers, with some long-term observational follow-up extending beyond a decade. Data for certain groups, especially those with multiple other health conditions, remain insufficient.

Overall, the research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. A key limitation is that many early trials lacked the statistical power or duration to definitively establish changes in hard endpoints like overall survival alone.

Key Studies & References

  1. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No 1901/2006, as amended URSODEOXYCHOLIC ACID
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ursodeoxycholic Acid JG (FAQ)

Q: What is the primary purpose of Ursodeoxycholic Acid JG?

A: Ursodeoxycholic Acid (UDCA) is a naturally occurring bile acid. It is commonly prescribed to dissolve certain types of gallstones (specifically those made of cholesterol) and to treat Primary Biliary Cholangitis (PBC), a liver condition.


Q: How does Ursodeoxycholic Acid JG relate to bile?

A: UDCA is a component of human bile. When taken as a medication, it works by changing the chemical composition of bile in the gallbladder and liver. This alteration can help to reduce the amount of cholesterol in the bile, which is necessary for cholesterol gallstones to dissolve. In PBC, the mechanism is complex, but it is thought to help protect liver cells.


Q: Is Ursodeoxycholic Acid JG taken long-term?

A: The duration of treatment with Ursodeoxycholic Acid JG varies depending on the condition being treated. For dissolving gallstones, treatment often lasts several months or longer and requires regular monitoring. Treatment for Primary Biliary Cholangitis is typically long-term (sometimes indefinite) to manage the condition.


Q: What are common side effects reported in studies of Ursodeoxycholic Acid JG?

A: Clinical study data indicates that the most commonly reported side effects are gastrointestinal, such as soft stools or diarrhea. Other less common effects may include nausea, vomiting, or stomach pain. Patients experiencing severe or persistent effects should seek medical advice.

Advertisements

How should Ursodeoxycholic Acid JG be stored and disposed of?

How to Store and Dispose of Ursodeoxycholic Acid

Ursodeoxycholic Acid (Ursodiol) must be stored strictly according to regulatory standards to maintain its effectiveness.

Storage Requirements

The medication must be stored at controlled room temperature, typically between 15 C and 30 C (or not above 25 C), and should be protected from light and moisture. To ensure proper protection, the medicine must be kept in its original container or package, and the container must be kept tightly closed.

For stability, scored half-tablets must be used within 28 days when stored at room temperature in the original packaging. For safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Official disposal guidance prohibits discarding this medicine via wastewater or household waste. Unused or expired medication must be disposed of according to local requirements. Individuals must ask a pharmacist how to dispose of medicines no longer required to comply with pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ursodeoxycholic Acid JG found in:

A-Z Index: